El-Shaddai Biologicals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 3.00 Cr
as on 16-12-2024
- Company Age 20 Year, 2 Months
- Last Filing with ROC 31 Mar 2012
- Open Charges ₹ 2.50 Cr
as on 16-12-2024
- Satisfied Charges ₹ 3.00 Cr
as on 16-12-2024
About El-Shaddai Biologicals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2012. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 3.00 Cr.
The company currently has active open charges totaling ₹2.50 Cr. The company has closed loans amounting to ₹3.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Baladrishnan Narayanan, Narayanasamy Balakrishnan, and Radhasankar Balakrishnan serve as directors at the Company.
- CIN/LLPIN
U24232TN2004PLC054527
- Company No.
054527
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Oct 2004
- Date of AGM
29 Sep 2012
- Date of Balance Sheet
31 Mar 2012
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at El-Shaddai Biologicals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Baladrishnan Narayanan  | Director | 21-Oct-2004 | Current |
| Narayanasamy Balakrishnan | Director | 02-Apr-2010 | Current |
| Radhasankar Balakrishnan | Director | 02-Apr-2010 | Current |
Financial Performance of El-Shaddai Biologicals.
Enhance accessibility to El-Shaddai Biologicals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of El-Shaddai Biologicals?
Unlock access to El-Shaddai Biologicals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Marksell Pharma LimitedActive 25 years 1 monthBaladrishnan Narayanan, Narayanasamy Balakrishnan and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 11 Dec 2006 | ₹2.50 Cr | Open |
3I Infotech Trusteeship Services Limited Creation Date: 21 Jan 2010 | ₹3.00 Cr | Satisfied |
How Many Employees Work at El-Shaddai Biologicals?
El-Shaddai Biologicals has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of El-Shaddai Biologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped El-Shaddai Biologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
